Theravance, Inc. (THRX) Announces Positive Topline Results From TD-1211 Phase 2b Study 0084 for the Treatment of Opioid-Induced Constipation
7/11/2012 9:47:31 AM
SOUTH SAN FRANCISCO, Calif., July 10, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:THRX) today announced positive topline results from 0084, the key study in the Phase 2b program evaluating TD-1211 as a potential treatment for chronic, non-cancer pain patients with opioid-induced constipation (OIC). TD-1211 is an investigational, orally administered, peripherally selective, multivalent inhibitor of the mu opioid receptor designed with the goal of alleviating gastrointestinal side effects of opioid therapy without affecting analgesia. These positive clinical results support progression into Phase 3 development for the treatment of patients with opioid-induced constipation.
comments powered by